跳至主要内容
临床试验/TCTR20190725001
TCTR20190725001招募中3 期

Precision treatment for Renal Osteodystrophy Guided by Bone Histomorphometry in Hemodialysis Patient with Low Bone Mineral Density

Faculty of Medicine, Chulalongkorn University0 个研究点目标入组 80 人开始时间: 2019年7月25日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • 1.Adult (Age ≥18-year-old)
  • 2.End-stage renal disease on chronic hemodialysis ≥ 3 months
  • 3.BMD T-score at the total hip, femoral neck, lumbar spine or distal forearm ≤ -2.5 or ≤ -1.0 with a presence of previous fragility fracture
  • 4.Serum intact parathyroid hormone (iPTH) level between 150 to 800 picogram per milliliter
  • 5.Tetracycline double-labelled trans-iliac bone biopsy with Histomorphometry
  • shown - low bone turnover disease (ABD) for Arm A and - high bone turnover disease for Arm B

排除标准

  • 1.Active malignancy or history of primary or secondary neoplasm of bone
  • 2.Bleeding tendency defined by: platelet counts < 150,000 per microliters, prolonged prothrombin time (PT) > 3 sec from normal control or activated partial thromboplastin time (APTT) > 2 times of normal control or currently taking anticoagulation or antiplatelets.
  • 3.Chronic heart failure, arrhythmias or chronic lung disease patient who unable to do prone position while biopsy procedure.
  • 4.History of allergy or severe adverse reaction to tetracycline and meperidine
  • 5.Pregnancy or breastfeeding
  • 6.Presence of connective tissue or bone disease affected in bone fragility e.g. rheumatoid arthritis, osteomalacia, chronic steroid use (prednisolone > 20mg/d for> 90 days)
  • 7.Presence of multiple prosthesis which unable to measure at least 1 site of DXA-BMD
  • 8.Current or previous use of osteoporosis medications.
  • 9.Presence of other cause of bone abnormality e.g. Aluminum toxicity, mixed renal osteodystrophy according to bone histology.
  • 10.History of allergy or severe adverse reaction to teriparatide and lanthanum (for arm A) and cinacalcet and calcitriol (for arm B)
  • 11.Corrected QT interval frome 12-leads EKG more than 500 milisecconds (for arm B)
  • 12.Anticipated living donor kidney transplant within study period

研究者

发起方
Faculty of Medicine&#44; Chulalongkorn University

相似试验

Precision treatment for Renal Osteodystrophy Guided... | 临床试验